Shannon N. Westin, MD, on Advanced or Recurrent Endometrial Cancer: DUO-E/GOG-3041/ENGOT-EN10
ESMO Congress 2026Advertisement
Shannon N. Westin, MD, of The University of Texas MD Anderson Cancer Center, reviews interim overall survival and safety results from a randomized phase III study evaluating durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib in patients with advanced/recurrent endometrial cancer (Abstract LBA37).
